Clinical trials: Mosquito-Borne Diseases
Japanese Encephalitis
Safety Surveillance After Immunization With IXIARO
This is an active electronic surveillance using data from the Defense Medical Surveillance System (DMSS) to detect and characterize serious, rare adverse events occurring within 42 days after vaccination with the Japanese…
- Trial name
- NCT01335412
- Testing
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Valneva Austria GmbH
Malaria, Dengue
Characterizing Humoral Immune Response to Mosquito Bites
The characteristics of the humoral response directed against mosquito saliva antigens are not known precisely. This is a major limitation for using immunological markers as an outcome in epidemiological trials and as an indicator…
- Trial name
- SG6 (NCT04478370)
- Testing
- Mosquito bites
- Where
- Thailand
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection
This is a clinical study to assess the safety of primary, secondary and tertiary blood-stage controlled human Plasmodium falciparum malaria infection of healthy malaria-naïve UK adults, as well as to evaluate any effect of prior…
- Trial name
- NCT03906474
- Testing
- Blood-stage controlled human P. falciparum malaria infection
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
IPTi in Mozambican Infants for Malaria Prevention
To evaluate if intermittent preventive treatment in infants (IPTi) consisting of SP [Fansidar] given through the EPI scheme alongside routine immunisations at 3, 4 and 9 months of age reduces de incidence of clinical malaria up…
- Trial name
- NCT00209794
- Testing
- Sulfadoxine-Pyrimethamine (Fansidar)
- Where
- Mozambique
- Volunteers
- 1,498 people
- Sponsor
- Hospital Clinic of Barcelona
Plasmodium Falciparum Infection
rCSP/AP10-602 [GLA-LSQ] Vaccine Trial
This is a study to evaluate the safety, immunogenicity, and efficacy of a recombinant circumsporozoite protein (rCSP) malaria vaccine administered with and without AP 10-602 [Glucopyranosyl Lipid A (GLA) in liposome Quillaja…
- Trial name
- NCT03589794
- Testing
- AP10-602, Malaria challenge, rCSP
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping
The purpose of this explorative clinical trial is to study parasite population dynamics, diversity and clearance kinetics of Plasmodium falciparum as well as determination of the molecular mechanisms associated with drug…
- Trial name
- NCT00336375
- Testing
- artemether-lumefantrine
- Where
- Tanzania
- Volunteers
- 50 people
- Sponsor
- Karolinska University Hospital
Dengue Fever
Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
Dengue fever is an acute febrile illness transmitted by mosquitoes, which affects half the world's population. There are 96 million symptomatic infections, 500,0000 hospitalisations and 25,000 deaths per year attributed to the…
- Trial name
- NCT02569827
- Testing
- Celgosivir, Modipafant 50mg, Modipafant 100mg
- Where
- Singapore
- Sponsor
- Singapore General Hospital
Malaria, Anemia
Uganda Housing Modification Study
To explore housing modification as a malaria control intervention, and to assess the degree to which it may offer protection in moderate to high malaria endemicity settings, we propose a two-phase study evaluating epidemiological…
- Trial name
- UHMS (NCT04622241)
- Testing
- Eave Tubes, Eave Ribbons, Full House Screening
- Where
- Uganda
- Volunteers
- 2,422 people, healthy volunteers welcome
- Sponsor
- Infectious Diseases Research Collaboration, Uganda
Seizure, Epilepsy
A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM
Pediatric cerebral malaria (CM) affects more than 3 million children each year killing ~20% and leaving one third of survivors with long term neurologic and psychiatric sequelae.
- Conditions
- Seizure, Epilepsy, Cerebral Malaria
- Trial name
- LVT2 (NCT01982812)
- Testing
- Oral Levetiracetam, Standard AED
- Where
- Malawi
- Volunteers
- 44 people
- Sponsor
- University of Rochester
Plasmodium Falciparum Infection
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms.
- Trial name
- AL3vs5 (NCT02020330)
- Testing
- Artemether-lumefantrine 3 days, Artemether-lumefantrine 5 days
- Where
- Burma
- Volunteers
- 150 people
- Sponsor
- University of Oxford
Malaria, Anemia
Intermittent Preventive Treatment With Antimalarials in Kenyan Infants
The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.
- Trial name
- NCT00111163
- Testing
- sulfadoxine-pyrimethamine with artesunate, amodiaquine with artesunate, chlorproguanil-dapsone
- Where
- Kenya
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Encephalitis, Japanese Encephalitis
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults.
- Trial name
- NCT00981175
- Testing
- Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sanofi
Malaria
Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon
To assess the efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine, in comparison with artemether-lumefantrine during 42 days follow up period in 720 children with acute uncomplicated P.
- Trial name
- NCT01845701
- Testing
- Artesunate-Amodiaquine, Dihydroartemisinine-Piperaquine, Artemether-lumefantrine combination
- Where
- 2 sites in Cameroon
- Volunteers
- 720 people
- Sponsor
- University of Yaounde 1
Plasmodium Falciparum Malaria
A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1
This is an open label, multi-centre phase I/IIa sporozoite-challenge trial to assess the safety, immunogenicity and efficacy of two combination ChAd63-MVA heterologous prime-boost vaccination regimens.
- Trial name
- NCT01739036
- Testing
- ChAd63 CS/ME-TRAP, MVA CS/ME-TRAP, ChAd63 CS/ME-TRAP/AMA1
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a…
- Trial name
- NCT05048875
- Testing
- Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
The purpose of this study is to assess efficacy and safety of a single low-dose Primaquine added to standard artemether/lumefantrine treatment for the clearance of Plasmodium falciparum gametocytes among patients with…
- Trial name
- NCT02090036
- Testing
- Primaquine (For artemether-lumefantrine+primaquine arm)
- Where
- Tanzania
- Volunteers
- 220 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Increased Drug Resistance, Asymptomatic Infection
Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic
Detection of the drug resistance molecular markers for falciparum and vivax in Longitudinal follow-up samples collected in Shwegyin Township, Bago Region that is Artemisinin Resistance Containment Tier I.
- Conditions
- Increased Drug Resistance, Asymptomatic Infection, Malaria
- Trial name
- NCT02708199
- Volunteers
- 1,179 people, healthy volunteers welcome
- Sponsor
- Department of Medical Research, Lower Myanmar
Malaria,Falciparum, Malaria in Pregnancy
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
The purpose of the INTREPiD study is to compare 1st trimester screening for malaria parasites with a high-sensitivity malaria rapid diagnostic test followed by treatment of test-positive women with artemether-lumefantrine (AL)…
- Conditions
- Malaria,Falciparum, Malaria in Pregnancy, Malaria in Childbirth, Pregnancy
- Trial name
- INTREPiD (NCT05757167)
- Testing
- Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT), Artemether-lumefantrine (AL)
- Where
- 2 sites in Democratic Republic of the Congo, Kenya
- Volunteers
- 2,174 people
- Sponsor
- Duke University
Malaria
Trial of Malaria Seasonal IPTc Combined With Community Case Management
Malaria is a major public health problem. 250 million cases annually leads to approximately 1 million deaths. Over 80 per cent of these deaths occur among African children under age five.
- Trial name
- NCT01449045
- Testing
- IPTc+CCM, Community Case Management with artemether-lumefantrine (AL)
- Where
- Senegal
- Volunteers
- 4,554 people, healthy volunteers welcome
- Sponsor
- Cheikh Anta Diop University, Senegal
Malaria, Pregnancy Malaria
LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial
Objective: The aim of this study is to evaluate the impact of enhanced malaria cases detection using molecular testing (LAMP) on maternal and infant morbidity and mortality in a prospective study design.
- Conditions
- Malaria, Pregnancy Malaria, Malaria in Pregnancy
- Trial name
- LAMPREG (NCT03754322)
- Testing
- LAMP, Microscopy/RDT
- Where
- 4 sites in Canada, Ethiopia
- Volunteers
- 2,424 people, healthy volunteers welcome
- Sponsor
- University of Calgary
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.